At least 7500 measles cases in the U.S. in 2026 priced at 19.5% on Polymarket, up 4.5 points, on $221K traded
No significant new platform headline in the last 30 minutes; news search recirculated only items already used today, taken by website-only batches, or on the banned list…
Full attribution under the DMCA, 17 U.S.C. § 512: an original Infiniti Intelligence report summarizing and linking to the publishers named above. All rights in the underlying reporting remain with them. Rights holders may request correction or removal via the contact address at infiniti.w3ai.io.
Polymarket’s contract on whether the U.S. will record at least 7500 measles cases in 2026 was priced at 19.5%, up 4.5 percentage points, with $221K traded, in the supplied market update published Oct 27, 2026 at 8:09 PM ET.
The price indicates that traders still assign the outcome a probability below one in five despite the upward move. It is a market-implied assessment, not a reported case count or a public-health forecast.
No fresh catalyst identified
The accompanying news scan identified no significant new platform headline in the preceding 30 minutes. Its results contained only previously reviewed or excluded material, leaving the supplied reporting without a clear new catalyst for the repricing.
According to predictionbubbles.net, its movers board compares probabilities over 24 hours and refreshes every 15 minutes using prices from Polymarket and Kalshi. The supplied page records a venue-data retrieval time of 28 Oct 2026, 00:12 UTC, but its text does not include the measles contract’s individual listing.
That limits what can be established beyond the headline figures. The material provides neither a current U.S. measles case count nor the contract’s settlement criteria, and it does not specify the period covered by the $221K trading figure. According to predictionbubbles.net, price movement and trading activity are separate measures; neither alone establishes market depth or explains why traders changed their assessment.
What it means for prediction markets
The change is in percentage points: The reported increase is 4.5 points, not a 4.5% relative gain.
A catalyst remains unverified: The supplied news scan does not connect the move to a fresh measles development.
Volume needs context: The $221K traded figure does not, by itself, establish liquidity or how much trading accompanied the latest move.
Resolution details matter: Without settlement criteria or case-count data, the supplied material cannot establish how close the outcome is to its threshold.